Skip to content

Effect of unani formulation in Psoriasis

Comparative study of Halela Siyah vs Halela Zard with Marham Kafoor as Topical Application in Plaque Psoriasis - A Randomized Single Blind Clinical Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044669
Enrollment
34
Registered
2022-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified Health Condition 2: L400- Psoriasis vulgaris

Interventions

Intervention1: Halela Siyah: Decoction of 10 grams of Halela siyah in 100 ml of water once a day on empty stomach for 45 days and marham kafoor for topical application for 45 days Control Intervention

Sponsors

Government Unani Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of up to moderate plaque psoriasis Patients with PASI score less than 10 Patients with chronicity of psoriasis less than 2 years Patients of all gender Patients in age groups of 18 to 65 years Willing and able to participate in the trial as an outpatient and comply with all trial requirements

Exclusion criteria

Exclusion criteria: Patients of Plaque psoriasis with PASI greater than 10 Patients with superadded skin infections like Eczema vitiligo Atopic dermatitis Contact dermatitis Tinea Pregnant and lactating mothers known case of renal insufficiency hepatic disorders and diabetes mellitus Patient on treatment with corticosteroids and PUVA Patients on medication with drugs that can aggravate psoriasis, like beta blockers calcium channel blockers or lithium History or evidence of drug or alcohol abuse Unwilling or unable to comply with the requirements of this protocol

Design outcomes

Primary

MeasureTime frame
Reduction in PASI score PGA and Photographic lesionsTimepoint: 0th 15th 30th and 45th day

Secondary

MeasureTime frame
Decrease in Psoriasis Quality of Life IndexTimepoint: 0th 15th 30th and 45th day

Countries

India

Contacts

Public ContactDr Mohammed Asjad

Government Unani Medical College and Hospital

ayesharafeeq81@yahoo.com9035158024

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026